左辉华,胡伟,周鹏,颜红兵

• 1:国家心血管病中心中国医学科学院阜外医院深圳医院冠心病中心
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心

摘要(Abstract)：

<正>大多数缺血性心脏病患者存在非ST段抬高型急性冠状动脉综合征(non-ST-segment elevation acute coronary syndrome, NSTE-ACS)。NSTE-ACS的处理始于正确的诊断、适时启动正确的药物治疗、合理实施冠状动脉造影和介入治疗以及开始二级预防。因此,高质量的指南对指导临床实践具有重要意义。每年欧洲心脏病学会(European Society of Cardiology,ESC)大会上的一个主要亮点是出版ESC临床实践指南。今年公布了包括《2020年ESC NSTEACS管理指南》(以下简称为《2020 ESC NSTE-ACS指南》)~([1-2])在内的4个指南。

关键词(KeyWords)： 非ST段抬高型急性冠状动脉综合征;欧洲心脏病学会;指南解读

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 左辉华,胡伟,周鹏,颜红兵

参考文献(References)：

• [1] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2020.[Epub ahead of print]
• [2] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:supplementary data. Eur Heart J,2020.[Epub ahead of print]
• [3] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J,2016,37(3):267-315.
• [4] Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with nonobstructive coronary arteries. Eur Heart J,2017,38(3):143-153.
• [5] Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease:a scientific statement from the American Heart Association. Circulation,2019,139(18):e891-e908.
• [6] Mortensen KH, Thuesen L, Kristensen IB, et al. Spontaneous coronary artery dissection:a Western Denmark Heart Registry study. Catheter Cardiovasc Interv,2009,74(5):710-717.
• [7] Nishiguchi T, Tanaka A, Ozaki Y, et al. Prevalence of spontaneous coronary artery dissection in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care,2016,5(3):263-270.
• [8] Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention:a consensus document from the Academic Research Consortium for high bleeding risk. Eur Heart J,2019,40(31):2632-2653.
• [9] Linde JJ, Kelbaek H, Hansen TF, et al. Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol,2020,75(5):453-463.
• [10] Chapman AR, Shah ASV, Lee KK, et al. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury.Circulation,2018,137(12):1236-1245.
• [11] Chew DP, Astley CM, Luker H, et al. A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes:rationale and design of the Australian GRACE Risk score Intervention Study(AGRIS). Am Heart J,2015,170(5):995-1004.
• [12] Cassese S, Byrne RA, Laugwitz KL, et al. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention:a meta-analysis of randomised trials. EuroIntervention,2015,11(2):196-203.
• [13] Zhang S, Gao W, Li H, et al. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention:a meta-analysis of randomized controlled trials. Int J Cardiol,2016,209:87-95.
• [14] Nuhrenberg TG, Hochholzer W, Mashayekhi K,et al. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes:a meta-analysis of randomizedcontrolled trials. Clin Res Cardiol,2018,107(9):807-815.
• [15] Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors:collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J,2015,36(27):1762-1771.
• [16] Barthélémy O, Jobs A, Meliga E, et al. Questions and answers on workup diagnosis and risk stratification:a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2020.[Epub ahead of print]
• [17] Barbato E, Mehilli J, Sibbing D, et al. Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome(NSTE-ACS):a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2020.[Epub ahead of print]
• [18] Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The task force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J,2011,32(23):2999-3054.
• [19] Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions:a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association(EHRA), European Association of Percutaneous Cardiovascular Interventions(EAPCI)and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS)and Asia-Pacific Heart Rhythm Society(APHRS). Eur Heart J,2014,35(45):3155-3179.
• [20] Schupke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med,2019,381(16):1524-1534.
• [21] Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med,2013,369(11):999-1010.
• [22] Dworeck C, Redfors B, Angera?s O,et al. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes.(Accepted for publication).
• [23]周金英，王莹，颜红兵.替格瑞洛单药治疗的理论依据与循证医学证据—从美国心脏病学会2020年会公布的3项研究说起.中国介入心脏病学杂志，2020,28(4):228-231.
• [24] Jobs A, Mehta SR, Montalescot G, et al. Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome:a meta-analysis of randomised trials. Lancet,2017,390(10096):737-746.
• [25] Bonello L, Laine M, Puymirat E, et al. Timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes and clinical outcomes:an updated meta-analysis.JACC Cardiovasc Interv, 2016,9(22):2267-2276.
• [26] Linde JJ, Kelbaek H, Hansen TF, et al. Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol,2020,75(5):453-463.